论文部分内容阅读
目的 报告 6 1例ⅢⅣ期肝癌的生存率 ,其中 5 3例采用不同方法治疗 ,探讨合理的治疗方法。 方法 17例单纯肝动脉导管化疗栓塞 (HAE) ;17例单纯放疗 (RT)和 6例低剂量放疗(LDRT) ;12例HAE +RT ;8例未做特殊治疗 (NT) ;1例单独免疫治疗 (BRM )。结果 6 1例的 1、2、3年绝对生存率是 4 7 5 %、2 4 6 %、8 6 % ,治疗 4 7例的 1、2、3年生存率是 6 1 7%、31 9%、11 4 % ,HAE +RT组 ;RT组 ;HAE组 ;NT和LDRT组的 1、2、3年生存率分别是 83 3%、5 8 3%、2 7 3% ;6 4 7%、35 3%、6 7% ;4 1 2 %、5 9%、0 ;HAE +RT组 ,HAE组与HAE之间生存率对比有明显差异 (P <0 0 5 )。 结论 HAE +RT组疗效好于HAE组 ,HAE组与RT组的接近 ,各治疗组结果均优于LDRT和NT组。笔者提出对晚期肝癌仍要采取积极治疗 ,但要根据肝功能和全身情况给予合理和适量的治疗 ,主张合理程序的综合治疗措施联合采用 :HAE、RT、BRM。
Objective To report the survival rate of 61 cases of stage ¢ ôⅣ hepatocellular carcinoma, of which 53 cases were treated by different methods to explore the reasonable treatment. Methods Seventeen patients underwent transcatheter arterial chemoembolization (HAE), 17 patients undergoing radiotherapy alone (RT) and 6 patients undergoing low-dose radiation therapy (LDRT), 12 patients with HAE + RT, 8 patients without special treatment (NT) Treatment (BRM). Results The absolute survival rates at 1, 2 and 3 years of 61 cases were 47.5%, 24.6% and 86.0%, respectively. The 1, 2 and 3-year survival rates of 47 cases were 61.7% and 31.9, respectively The 1, 2, 3-year survival rates of the HA and HAE groups were 83.3%, 58.3%, 27.3% and 64.7%, respectively , 35 3%, 67%, 41 2%, 59%, 0 respectively. There was significant difference in the survival rate between HAE + RT group and HAE group and HAE group (P <0.05). Conclusion The curative effect of HAE + RT group is better than that of HAE group and HAE group is close to that of RT group. The results of each treatment group are better than that of LDRT and NT groups. The author proposes to take active treatment for advanced liver cancer, but according to liver function and systemic conditions to give a reasonable and appropriate treatment, advocating a comprehensive treatment of rational procedures jointly adopted: HAE, RT, BRM.